Promethera Biosciences treats first patients with Promethera(R) HepaStem

Promethera Biosciences, a Belgian biotechnology company developing Promethera(R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, today announces it has treated its first two patients with its innovative treatment based on allogeneic adult liver stem cell technology (HepaStem). These patients were treated and are followed at the Cliniques Universitaires Saint-Luc (Brussels, Belgium). 
 
The trial, a prospective, open label multicenter phase I/II study testing Promethera(R)HepaStem is designed to evaluate the safety and the preliminary efficacy of Promethera(R)HepaStem in Urea Cycle Disorders and Crigler-Najjar Syndrome patients. 

“We are delighted to have achieved this important milestone in HepaStem’s development” said Eric Halioua, co-founder and CEO of Promethera Biosciences.

“HepaStem is an innovation in the field of liver-based metabolic diseases,” said Dr. Beatrice De Vos, chief medical officer of Promethera Biosciences. “This clinical trial will be the very first to apply allogeneic liver progenitor cells. This treatment with progenitor cells will contribute to restore a deficient enzyme function in Urea Cycle Diseases or in a Crigler-Najjar syndrome.”

The major innovation of PrometheraAir Jordan 1